Asahi shares mark weekly slide after cyberattack halts production
Eric W. Roberts, a director and chief business officer at CalciMedica, Inc. (NASDAQ:CALC), purchased 3,400 shares of common stock on September 15, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The purchase comes as the stock has declined nearly 11% over the past week, though it maintains a strong 52% gain over the past six months, according to InvestingPro data.
The shares were bought at a weighted average price of $2.6779, with individual prices ranging from $2.65 to $2.70, for a total transaction value of $9,104. Roberts acquired the shares through FMTC Custodian - Roth IRA FBO Eric W. Roberts. Following the transaction, Roberts directly and indirectly owns a total of 1,097,837 shares of CalciMedica. The company maintains a strong balance sheet with more cash than debt, while analysts have set price targets between $14-$20. Track insider transactions and access 10 additional key insights with InvestingPro.
In other recent news, CalciMedica Inc. announced the publication of a manuscript in the American Journal of Nephrology. The manuscript outlines the design and rationale of its Phase 2 KOURAGE trial, which focuses on the use of Auxora in treating acute kidney injury (AKI) with respiratory failure. Preclinical data included in the publication indicate that Auxora significantly increased the glomerular filtration rate in rat models of AKI. Additionally, a post-hoc analysis from the company’s CARDEA trial was presented, showing a 62.7% relative reduction in mortality among COVID-19 patients with AKI who received Auxora compared to those given a placebo. These developments highlight CalciMedica’s ongoing efforts in advancing treatments for kidney-related conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.